Skip to main content

Advertisement

SpringerLink
Log in

Pediatric issues in new therapies for hepatitis B and C

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Two antiviral treatments have been approved for hepatitis B virus (HBV) infection by the US Food and Drug Administration (FDA) for use in children: interferon (IFN)-α, 6 MU/m2 three times a week subcutaneously for 6 months, and lamivudine, 3 mg/kg/d orally for 12 months. Twenty-six percent to 58% of children treated with IFN become HBV DNA negative, and up to 38% become negative to hepatitis B e antigen (HBeAg). Lamivudine, a nucleoside analogue that blocks viral replication by inhibition of the HBV polymerase, has been associated with comparable rates of seroconversion of HBeAg to anti-HBe. Loss of surface antigen occurs in less than 5% of patients treated with lamivudine, compared with 3% to 33% in those treated with IFN-α. Fifty percent to 65% of children treated with lamivudine clear HBV DNA after 12 months of therapy, but relapse rates have not been clarified. Patients treated with lamivudine develop drug-resistant (YMDD) mutants in the HBV polymerase at the rate of 16% to 32% per year. No treatments for children with hepatitis C virus (HCV) have been approved by the FDA. However, published reports describe treatment with IFN monotherapy and combination therapy with IFN and ribavirin. Trials of PEG-IFN alone or in combination with ribavirin are in progress. Given the lack of data regarding treatment of HCV in children, it is generally agreed among pediatric hepatologists that the optimal treatment is within the context of randomized, controlled trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hsu HM, Lu CF, Lee SC, et al.: Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis 1999, 179:367–370.

    Article  PubMed  CAS  Google Scholar 

  2. Viviani S, Jack A, Hall AJ, et al.: Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999, 17:2946–2950.

    Article  PubMed  CAS  Google Scholar 

  3. Mahoney FJ, Woodruff BA, Erben JJ, et al.: Effect of hepatitis B vaccination program on the prevalence of hepatitis B virus infection. J Infect Dis 1993, 167:203–207.

    PubMed  CAS  Google Scholar 

  4. Chang MH, Chen CJ, Lai et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855–1859.

    Article  PubMed  CAS  Google Scholar 

  5. Goldstein ST, Fiore AE: Toward the global elimination of hepatitis B virus transmission. J Pediatr 2001, 139:343–345.

    Article  PubMed  CAS  Google Scholar 

  6. Armstrong GL, Mast EE, Wojczynski M, Margolis HS: Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics 2001, 108:1123–1128.

    Article  PubMed  CAS  Google Scholar 

  7. Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver. Can J Gastroenterol 2000, 14:5B-20B.

  8. Chongrisawat V, Poovorawan Y: Management of chronic hepatitis B and C virus infections. Indian J Pediatr 2002, 69:149–154. An excellent overview of the natural history, diagnostic techniques, and treatment options for children chronically infected with either HBV or HCV from the Virus Hepatitis Research Unit in Bangkok, Thailand, where these pediatric infections are common.

    Google Scholar 

  9. Sokal EM, Conjeevaram HS, Roberts EA, et al.: Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998, 114:988–995.

    Article  PubMed  CAS  Google Scholar 

  10. Bortolotti F, Jara P, Barbera C et al.: Long-term effect of alpha interferon in children with chronic hepatitis B. Gut 2000, 46:715–718.

    Article  PubMed  CAS  Google Scholar 

  11. Jara P, Bortolotti F: Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999, 29:163–170.

    Article  PubMed  CAS  Google Scholar 

  12. Barlow CF, Priebe CJ, Mulliken JB, et al.: Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1988, 132:527–530.

    Google Scholar 

  13. Sokal EM, Roberts EA, Mieli-Vergani G, et al.: A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000, 44:590–597.

    Article  PubMed  CAS  Google Scholar 

  14. Jonas MM, Kelley DA, Mizerski J, et al.: Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002, 346:1706–1713. This randomized, controlled multinational trial of 288 children with chronic HBV is designed well and should serve as a model for future antiviral trials in children with HBV.

    Article  PubMed  CAS  Google Scholar 

  15. Dikici B, Bosnak M, Bosnak V, et al.: Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatrics Int 2002, 44:517–521.

    Article  CAS  Google Scholar 

  16. Shapira R, Mor E, Bar-Nathan N, et al.: Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children. Transplantation 2001, 72:333–336.

    Article  PubMed  CAS  Google Scholar 

  17. Shapira R, Daudi N, Klein A, et al.: Seroconversion after the addition of famciclovir therapy in a child with hepatitis B virus infection after liver transplantation who developed lamivudine resistance. Transplantation 2002, 73:820–821.

    Article  PubMed  Google Scholar 

  18. Bhimma R, Coovadia HM, Kramvis A, et al.: Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002, 17:393–399.

    Article  PubMed  Google Scholar 

  19. Ohto H, Terazawa S, Sasaki N, et al.: Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994, 330:744–750.

    Article  PubMed  CAS  Google Scholar 

  20. Zanetti AR, Tanzi E, Romano L et al.: A prospective study of mother-to-infant transmission of hepatitis C virus. Interviology 1998, 41:208–212.

    Article  CAS  Google Scholar 

  21. Thomas DL, Villano SA, Riester KA et al.: Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998, 177:1480–1488.

    PubMed  CAS  Google Scholar 

  22. Chang MH, Ni YM, Hwang LH et al.: Long term clinical and virologic outcome of primary hepatitis C virus infection in children: a prospective study. Pediatr Infect Dis J 1994, 13:769–773.

    Article  PubMed  CAS  Google Scholar 

  23. Vogt M, Lang T, Frosner G et al.: Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999, 341:866–870.

    Article  PubMed  CAS  Google Scholar 

  24. Zancan L, Strafella MS, Brugiolo A, et al. Chronic hepatitis C virus infection in childhood and early cirrhosis: Is it possible? J Pediatr Gastroenterol Nutr 2000, 30:350–351.

    Article  PubMed  CAS  Google Scholar 

  25. Mast EE, Alter MJ, Margolis HS: Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999, 17:1730–1733.

    Article  PubMed  CAS  Google Scholar 

  26. Kesson AM: Review article: Diagnosis and management of paediatric hepatitis C virus infection. J Paediatr Child Health 2002, 38:213–218. An excellent review of diagnostic techniques, epidemiology, and management considerations for HCV in the pediatric age group.

    Article  PubMed  CAS  Google Scholar 

  27. Jacobson KB, Murray K, Zellos A, Schwarz KB: An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002, 343:52–58. A review of the 366 treated and 105 untreated children with chronic hepatitis C reported in the English language. Includes a critique of the largely uncontrolled trials and makes recommendations for improving study design in the future.

    Google Scholar 

  28. Carithers RL, Emerson SS: Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997, 26(bdSuppl):83S-88S.

    Article  PubMed  CAS  Google Scholar 

  29. Davison S: Chronic hepatitis. In Diseases of the Liver and Biliary System in Children, edn 1. Edited by Kelly DA. Oxford: Blackwell Science; 1999:97–123.

    Google Scholar 

  30. Bunn S, Kelly D, Murray KF, et al.: Safety, efficacy and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic hepatitis C [abstract]. Hepatology 2000, 32:350A.

    Google Scholar 

  31. Woynarowski M, Socha J, Kuidowicz J, et al.: Interferon+ ribavirin vs interferon alone in treatment of children with chronic HCV infection [abstract]. J Hepatic 2001, 34(Suppl 1):139S.

    Google Scholar 

  32. Lackner H, Moser A, Deutsch J, et al.: Interferon-alfa and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000, 106:1–4.

    Article  Google Scholar 

  33. Christensson B, Wiebe T, Akesson A, et al.: Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000, 30:585–586.

    Article  PubMed  CAS  Google Scholar 

  34. Wirth S, Lang T, Gehring S, Gerner P: Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002, 36:1280–1284.

    Article  PubMed  CAS  Google Scholar 

  35. Li CK, Chan PK, Ling SC, Ha SY: Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassemia major. Br J Maematol 2002, 117:755–758.

    Article  CAS  Google Scholar 

  36. Strader DB: Understudied populations with hepatitis C. Hepatology 2002, 36:S226-S236.

    Article  PubMed  Google Scholar 

  37. Mathurin P, Mouquet C, Poynard T, et al.: Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 1999, 29:257–263.

    Article  PubMed  CAS  Google Scholar 

  38. Rostaing L, Modesto A, Baron E, et al.: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996, 74:512–516.

    PubMed  CAS  Google Scholar 

  39. Resti M, Azzari C, Bortolotti F. Hepatitis C virus infection in children coinfected with HIV. Pediatr Drugs 2002, 4:571–580. An excellent review of the epidemiology, viral interactions, and treatment considerations of coinfected children. It also contains an up-todate review of treatment results in children infected with HCV alone.

    Google Scholar 

  40. Ruiz Moreno M, Jiminez J, Porres JC, et al.: A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990, 45:26–33.

    Google Scholar 

  41. Ruiz Moreno M, Rua MJ, Molina J, et al.: Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991, 13:1035–1039.

    Google Scholar 

  42. Utili R, Sagnelli E, Galanti B, et al.: Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2ainterferon: a controlled, randomized study. Am J Gastroenterol 1991, 86:327–330.

    PubMed  CAS  Google Scholar 

  43. Sokal EM, Wirth S, Goyens P, et al.: Interferon alfa-2b therapy in children with chronic hepatitis B. Gut 1993, 34:S87-S90.

    PubMed  CAS  Google Scholar 

  44. Barbera C, Bortolotti F, Crivellaro C, et al.: Recombinant interferon-alpha 2a hastens the rate of HbeAg clearance in children with chronic hepatitis B. Hepatology 1994, 20:287–290.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Gastroenterology and Nutrition, Johns Hopkins Children’s Center, 600 North Wolfe Street, Brady 320, 21287, Baltimore, MD, USA

    Kathleen B. Schwarz MD

Authors
  1. Kathleen B. Schwarz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwarz, K.B. Pediatric issues in new therapies for hepatitis B and C. Curr Gastroenterol Rep 5, 233–239 (2003). https://doi.org/10.1007/s11894-003-0025-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-003-0025-7

Keywords

Search

Navigation